Jon Wigginton, MD

Jon Wigginton, MD, currently serves as the President of Research and Development at Bright Peak Therapeutics, a position he has held since August 2022. His role involves overseeing all research and development functions, including discovery, manufacturing, clinical research, and regulatory affairs. He collaborates closely with the CEO and Executive Committee on corporate strategy and interfaces with investors and partners.13

Professional Background

Dr. Wigginton has over 25 years of experience in clinical oncology and drug development. Before joining Bright Peak Therapeutics, he was the Chief Medical Officer at MacroGenics, where he led clinical development programs. He also held significant roles at Bristol Myers Squibb, including Therapeutic Area Head for Immuno-Oncology.23 His early career included a notable tenure at the National Cancer Institute, where he was the Head of the Investigational Biologics Section.14

Education

Dr. Wigginton earned his M.D. from the University of Michigan, where he also completed his undergraduate studies in biology.23

Additional Roles

In addition to his work at Bright Peak, he is a member of the Board of Directors for Sutro Biopharma and has held various leadership positions in organizations such as the Society for Immunotherapy of Cancer (SITC).12

Dr. Wigginton's extensive experience positions him as a prominent figure in the field of cancer immunotherapy, particularly in developing novel cytokine-based therapeutics.34